# Instil Bio Posts $0.62 GAAP Loss Per Share, $0.48 Non-GAAP Loss Per Share

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58393
Published: 2026-11-16T13:38:24.000Z
Updated: 2026-11-16T13:38:24.000Z
Section: Business

> Instil Bio expects its $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027.

Instil Bio posted a $4.231 million net loss for the quarter ended Sept. 30. It expects its $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027.

The biotechnology company announced its results Nov. 16 at 7 a.m. ET (12:00 UTC). Its GAAP loss was $0.62 per basic and diluted share, and its non-GAAP loss was $0.48 per share.

Instil Bio’s non-GAAP calculation excludes noncash stock-based compensation, restructuring charges and impairment charges. Instil Bio advances treatment candidates through subsidiaries organized around individual assets, including programs it develops or licenses.

As of Sept. 30, Instil Bio held $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments. It expects those resources to fund its operating plan through 2027.


